Ample opportunity

While some investors are sifting through formerly high-flying names for bargains, event-driven buysiders have a full plate of late-stage milestones in 2Q16. The quarter promises more than 30 Phase III data readouts and PDUFA dates.

The most eagerly anticipated data events may or may not come this quarter. Biogen Inc. has guided toward results for remyelinating antibody BIIB033 to treat multiple sclerosis around mid-year, as has Merck & Co. Inc. for data for Keytruda pembrolizumab as first-line therapy for lung cancer (see "2Q Milestones," page 10)...